This article describes the pharmacology of approved parenteral anticoagulants. These
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight …

Venous thromboembolism (VTE) is a serious and often fatal medical condition with an
increasing incidence. Despite the changing landscape of VTE treatment with the introduction …

Organisation mondiale de la Santé 2022 Certains droits réservés. La présente œuvre est
disponible sous la licence Creative Commons Attribution Pas d'utilisation commerciale …

This chapter describes the pharmacology of approved parenteral anticoagulants, including
the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy: American …

Current guidelines for heparin-induced thrombocytopenia (HIT) management recommend
heparin cessation and switching to a nonheparin anticoagulant (ie, argatroban, danaparoid) …

Background The effectiveness and safety of non‐heparin anticoagulants for the treatment of
heparin‐induced thrombocytopenia (HIT) are not fully established, and the optimal treatment …

Elderly people represent a patient population at high thromboembolic risk, but also at high
hemorrhagic risk. There is a general tendency among physicians to underuse …

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that is
characterized by platelet activation, hypercoagulability, and a resulting increased risk for …

Heparin-induced thrombocytopenia (HIT) has a distinct clinical profile and unique
pathogenesis. It is caused by platelet-activating IgG antibodies that recognize …